+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Active Pharmaceutical Ingredient (API) Market in India 2026-2030

  • PDF Icon

    Report

  • 200 Pages
  • June 2026
  • Region: India
  • TechNavio
  • ID: 5941990
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The active pharmaceutical ingredient (api) market in india is forecasted to grow by USD 11.79 billion during 2025-2030, accelerating at a CAGR of 7.4% during the forecast period. The report on the active pharmaceutical ingredient (api) market in india provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising domestic healthcare expenditure and prevalence of chronic conditions, growing emphasis on biosimilars manufacturing, expansion of global export demand and contract manufacturing sectors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

The active pharmaceutical ingredient (api) market in india is segmented as below:

By Manufacturing Type

  • Captive APIs
  • Contract APIs

By Type

  • Innovative APIs
  • Generic APIs

By Product Type

  • Prescription
  • Over-the-counter (OTC)

By Application

  • Cardiovascular diseases (CVDs)
  • Oncology
  • Infectious diseases
  • Diabetes
  • Others

By Geography

  • APAC
  • India
This study identifies the accelerated digitization and integration of artificial intelligence in process synthesis as one of the prime reasons driving the active pharmaceutical ingredient (api) market in india growth during the next few years. Also, structural pivot toward continuous manufacturing systems and advanced flow chemistry and strategic integration of sustainability and green chemistry principles in chemical synthesis will lead to sizable demand in the market.

The report on the active pharmaceutical ingredient (api) market in india covers the following areas:

  • Active pharmaceutical ingredient (api) market in india sizing
  • Active pharmaceutical ingredient (api) market in india forecast
  • Active pharmaceutical ingredient (api) market in india industry analysis
A robust vendor analysis within the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredient (api) market in india vendors that include Aarti Industries Ltd., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Divis Laboratories Ltd., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Granules India Ltd., HIKAL Ltd., Ipca Laboratories, Jubilant Pharmova Ltd., Laurus Labs Ltd., Lupin Ltd., Neuland Laboratories, Piramal Pharma Solutions, Shilpa Medicare Ltd., Strides Pharma Ltd., Sun Pharmaceutical Industries, Syngene International Ltd. Also, the active pharmaceutical ingredient (api) market in india analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Country Market Characteristics
  • Executive Summary - Chart on Market Segmentation by Manufacturing Type
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Product Type
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Company Market Positioning
2 Market Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
  • Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
  • Overview on factors of disruption
2.4 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
3 Market Landscape
3.1 Market ecosystem
  • Chart on Parent Market
  • Data Table on - Parent Market
3.2 Market characteristics
  • Chart on Market characteristics analysis
3.3 Value chain analysis
  • Chart on Value chain analysis
4 Market Sizing
4.1 Market definition
  • Data Table on Offerings of companies included in the market definition
4.2 Market segment analysis
  • Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030
  • Chart on India - Market size and forecast 2025-2030 ($ million)
  • Data Table on India - Market size and forecast 2025-2030 ($ million)
  • Chart on India: Year-over-year growth 2025-2030 (%)
  • Data Table on India: Year-over-year growth 2025-2030 (%)
5 Historic Market Size
5.1 Active Pharmaceutical Ingredient (API) Market in India 2020 - 2024
  • Historic Market Size - Data Table on Active Pharmaceutical Ingredient (API) Market in India 2020 - 2024 ($ million)
5.2 Manufacturing Type segment analysis 2020 - 2024
  • Historic Market Size - Manufacturing Type Segment 2020 - 2024 ($ million)
5.3 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
5.4 Product Type segment analysis 2020 - 2024
  • Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
5.5 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
6.1 Impact of AI on active pharmaceutical ingredient (API) market in India
6.2 Impact of geopolitical conflicts on active pharmaceutical ingredient (API) market in India
7 Five Forces Analysis
7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition
  • Chart on Market condition - Five forces 2025 and 2030
8 Market Segmentation by Manufacturing Type
8.1 Market segments
  • Chart on Manufacturing Type - Market share 2025-2030 (%)
  • Data Table on Manufacturing Type - Market share 2025-2030 (%)
8.2 Comparison by Manufacturing Type
  • Chart on Comparison by Manufacturing Type
  • Data Table on Comparison by Manufacturing Type
8.3 Captive APIs - Market size and forecast 2025-2030
  • Chart on Captive APIs - Market size and forecast 2025-2030 ($ million)
  • Data Table on Captive APIs - Market size and forecast 2025-2030 ($ million)
  • Chart on Captive APIs - Year-over-year growth 2025-2030 (%)
  • Data Table on Captive APIs - Year-over-year growth 2025-2030 (%)
8.4 Contract APIs - Market size and forecast 2025-2030
  • Chart on Contract APIs - Market size and forecast 2025-2030 ($ million)
  • Data Table on Contract APIs - Market size and forecast 2025-2030 ($ million)
  • Chart on Contract APIs - Year-over-year growth 2025-2030 (%)
  • Data Table on Contract APIs - Year-over-year growth 2025-2030 (%)
8.5 Market opportunity by Manufacturing Type
  • Market opportunity by Manufacturing Type ($ million)
  • Data Table on Market opportunity by Manufacturing Type ($ million)
9 Market Segmentation by Type
9.1 Market segments
  • Chart on Type - Market share 2025-2030 (%)
  • Data Table on Type - Market share 2025-2030 (%)
9.2 Comparison by Type
  • Chart on Comparison by Type
  • Data Table on Comparison by Type
9.3 Innovative APIs - Market size and forecast 2025-2030
  • Chart on Innovative APIs - Market size and forecast 2025-2030 ($ million)
  • Data Table on Innovative APIs - Market size and forecast 2025-2030 ($ million)
  • Chart on Innovative APIs - Year-over-year growth 2025-2030 (%)
  • Data Table on Innovative APIs - Year-over-year growth 2025-2030 (%)
9.4 Generic APIs - Market size and forecast 2025-2030
  • Chart on Generic APIs - Market size and forecast 2025-2030 ($ million)
  • Data Table on Generic APIs - Market size and forecast 2025-2030 ($ million)
  • Chart on Generic APIs - Year-over-year growth 2025-2030 (%)
  • Data Table on Generic APIs - Year-over-year growth 2025-2030 (%)
9.5 Market opportunity by Type
  • Market opportunity by Type ($ million)
  • Data Table on Market opportunity by Type ($ million)
10 Market Segmentation by Product Type
10.1 Market segments
  • Chart on Product Type - Market share 2025-2030 (%)
  • Data Table on Product Type - Market share 2025-2030 (%)
10.2 Comparison by Product Type
  • Chart on Comparison by Product Type
  • Data Table on Comparison by Product Type
10.3 Prescription - Market size and forecast 2025-2030
  • Chart on Prescription - Market size and forecast 2025-2030 ($ million)
  • Data Table on Prescription - Market size and forecast 2025-2030 ($ million)
  • Chart on Prescription - Year-over-year growth 2025-2030 (%)
  • Data Table on Prescription - Year-over-year growth 2025-2030 (%)
10.4 Over-the-counter (OTC) - Market size and forecast 2025-2030
  • Chart on Over-the-counter (OTC) - Market size and forecast 2025-2030 ($ million)
  • Data Table on Over-the-counter (OTC) - Market size and forecast 2025-2030 ($ million)
  • Chart on Over-the-counter (OTC) - Year-over-year growth 2025-2030 (%)
  • Data Table on Over-the-counter (OTC) - Year-over-year growth 2025-2030 (%)
10.5 Market opportunity by Product Type
  • Market opportunity by Product Type ($ million)
  • Data Table on Market opportunity by Product Type ($ million)
11 Market Segmentation by Application
11.1 Market segments
  • Chart on Application - Market share 2025-2030 (%)
  • Data Table on Application - Market share 2025-2030 (%)
11.2 Comparison by Application
  • Chart on Comparison by Application
  • Data Table on Comparison by Application
11.3 Cardiovascular diseases (CVDs) - Market size and forecast 2025-2030
  • Chart on Cardiovascular diseases (CVDs) - Market size and forecast 2025-2030 ($ million)
  • Data Table on Cardiovascular diseases (CVDs) - Market size and forecast 2025-2030 ($ million)
  • Chart on Cardiovascular diseases (CVDs) - Year-over-year growth 2025-2030 (%)
  • Data Table on Cardiovascular diseases (CVDs) - Year-over-year growth 2025-2030 (%)
11.4 Oncology - Market size and forecast 2025-2030
  • Chart on Oncology - Market size and forecast 2025-2030 ($ million)
  • Data Table on Oncology - Market size and forecast 2025-2030 ($ million)
  • Chart on Oncology - Year-over-year growth 2025-2030 (%)
  • Data Table on Oncology - Year-over-year growth 2025-2030 (%)
11.5 Infectious diseases - Market size and forecast 2025-2030
  • Chart on Infectious diseases - Market size and forecast 2025-2030 ($ million)
  • Data Table on Infectious diseases - Market size and forecast 2025-2030 ($ million)
  • Chart on Infectious diseases - Year-over-year growth 2025-2030 (%)
  • Data Table on Infectious diseases - Year-over-year growth 2025-2030 (%)
11.6 Diabetes - Market size and forecast 2025-2030
  • Chart on Diabetes - Market size and forecast 2025-2030 ($ million)
  • Data Table on Diabetes - Market size and forecast 2025-2030 ($ million)
  • Chart on Diabetes - Year-over-year growth 2025-2030 (%)
  • Data Table on Diabetes - Year-over-year growth 2025-2030 (%)
11.7 Others - Market size and forecast 2025-2030
  • Chart on Others - Market size and forecast 2025-2030 ($ million)
  • Data Table on Others - Market size and forecast 2025-2030 ($ million)
  • Chart on Others - Year-over-year growth 2025-2030 (%)
  • Data Table on Others - Year-over-year growth 2025-2030 (%)
11.8 Market opportunity by Application
  • Market opportunity by Application ($ million)
  • Data Table on Market opportunity by Application ($ million)
12 Customer Landscape
12.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
13 Drivers, Challenges, and Opportunity
13.1 Market drivers
  • Rising domestic healthcare expenditure and prevalence of chronic conditions
  • Growing emphasis on biosimilars manufacturing
  • Expansion of global export demand and contract manufacturing sectors
13.2 Market challenges
  • Margin compression from increasing costs of raw inputs and global price volatility
  • Restrictive environmental compliance regimes and complex regulatory oversight
  • Persistent structural reliance on foreign input material and core supply chains
13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
13.4 Market opportunities
  • Accelerated digitization and integration of artificial intelligence in process synthesis
  • Structural pivot toward continuous manufacturing systems and advanced flow chemistry
  • Strategic integration of sustainability and green chemistry principles in chemical synthesis
14 Competitive Landscape
14.1 Overview
14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
  • Overview on factors of disruption
14.4 Industry risks
  • Impact of key risks on business
15 Competitive Analysis
15.1 Companies profiled
  • Companies covered
15.2 Company ranking index
  • Company ranking index
15.3 Market positioning of companies
  • Matrix on companies position and classification
15.4 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Business segments
  • Aurobindo Pharma Ltd. - Key news
  • Aurobindo Pharma Ltd. - Key offerings
  • Aurobindo Pharma Ltd. - Segment focus
  • SWOT
15.5 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
15.6 Divis Laboratories Ltd.
  • Divis Laboratories Ltd. - Overview
  • Divis Laboratories Ltd. - Product / Service
  • Divis Laboratories Ltd. - Key offerings
  • SWOT
15.7 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
15.8 Glenmark Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd. - Overview
  • Glenmark Pharmaceuticals Ltd. - Product / Service
  • Glenmark Pharmaceuticals Ltd. - Key news
  • Glenmark Pharmaceuticals Ltd. - Key offerings
  • SWOT
15.9 Granules India Ltd.
  • Granules India Ltd. - Overview
  • Granules India Ltd. - Product / Service
  • Granules India Ltd. - Key offerings
  • SWOT
15.10 Ipca Laboratories
  • Ipca Laboratories - Overview
  • Ipca Laboratories - Product / Service
  • Ipca Laboratories - Key offerings
  • SWOT
15.11 Jubilant Pharmova Ltd.
  • Jubilant Pharmova Ltd. - Overview
  • Jubilant Pharmova Ltd. - Business segments
  • Jubilant Pharmova Ltd. - Key offerings
  • Jubilant Pharmova Ltd. - Segment focus
  • SWOT
15.12 Laurus Labs Ltd.
  • Laurus Labs Ltd. - Overview
  • Laurus Labs Ltd. - Product / Service
  • Laurus Labs Ltd. - Key offerings
  • SWOT
15.13 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
15.14 Piramal Pharma Solutions
  • Piramal Pharma Solutions - Overview
  • Piramal Pharma Solutions - Business segments
  • Piramal Pharma Solutions - Key offerings
  • Piramal Pharma Solutions - Segment focus
  • SWOT
15.15 Shilpa Medicare Ltd.
  • Shilpa Medicare Ltd. - Overview
  • Shilpa Medicare Ltd. - Product / Service
  • Shilpa Medicare Ltd. - Key offerings
  • SWOT
15.16 Strides Pharma Ltd.
  • Strides Pharma Ltd. - Overview
  • Strides Pharma Ltd. - Product / Service
  • Strides Pharma Ltd. - Key offerings
  • SWOT
15.17 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
15.18 Syngene International Ltd.
  • Syngene International Ltd. - Overview
  • Syngene International Ltd. - Product / Service
  • Syngene International Ltd. - Key offerings
  • SWOT
16 Appendix
16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
16.4 Research methodology
  • Research methodology
16.5 Data procurement
  • Information sources
16.6 Data validation
  • Data validation
16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
16.8 Data synthesis
  • Data synthesis
16.9 360 degree market analysis
  • 360 degree market analysis
16.10 List of abbreviations
  • List of abbreviations
List of Exhibits
Exhibit 1: Executive Summary - Chart on Market Overview
Exhibit 2: Executive Summary - Data Table on Market Overview
Exhibit 3: Executive Summary - Chart on Country Market Characteristics
Exhibit 4: Executive Summary - Chart on Market Segmentation by Manufacturing Type
Exhibit 5: Executive Summary - Chart on Market Segmentation by Type
Exhibit 6: Executive Summary - Chart on Market Segmentation by Product Type
Exhibit 7: Executive Summary - Chart on Market Segmentation by Application
Exhibit 8: Executive Summary - Chart on Company Market Positioning
Exhibit 9: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 10: Overview on criticality of inputs and factors of differentiation
Exhibit 11: Overview on factors of disruption
Exhibit 12: Impact of drivers and challenges in 2025 and 2030
Exhibit 13: Chart on Parent Market
Exhibit 14: Data Table on - Parent Market
Exhibit 15: Chart on Market characteristics analysis
Exhibit 16: Chart on Value chain analysis
Exhibit 17: Data Table on Offerings of companies included in the market definition
Exhibit 18: Market segments
Exhibit 19: Chart on India - Market size and forecast 2025-2030 ($ million)
Exhibit 20: Data Table on India - Market size and forecast 2025-2030 ($ million)
Exhibit 21: Chart on India: Year-over-year growth 2025-2030 (%)
Exhibit 22: Data Table on India: Year-over-year growth 2025-2030 (%)
Exhibit 23: Historic Market Size - Data Table on Active Pharmaceutical Ingredient (API) Market in India 2020 - 2024 ($ million)
Exhibit 24: Historic Market Size - Manufacturing Type Segment 2020 - 2024 ($ million)
Exhibit 25: Historic Market Size - Type Segment 2020 - 2024 ($ million)
Exhibit 26: Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
Exhibit 27: Historic Market Size - Application Segment 2020 - 2024 ($ million)
Exhibit 28: Five forces analysis - Comparison between 2025 and 2030
Exhibit 29: Bargaining power of buyers - Impact of key factors 2025 and 2030
Exhibit 30: Bargaining power of suppliers - Impact of key factors in 2025 and 2030
Exhibit 31: Threat of new entrants - Impact of key factors in 2025 and 2030
Exhibit 32: Threat of substitutes - Impact of key factors in 2025 and 2030
Exhibit 33: Threat of rivalry - Impact of key factors in 2025 and 2030
Exhibit 34: Chart on Market condition - Five forces 2025 and 2030
Exhibit 35: Chart on Manufacturing Type - Market share 2025-2030 (%)
Exhibit 36: Data Table on Manufacturing Type - Market share 2025-2030 (%)
Exhibit 37: Chart on Comparison by Manufacturing Type
Exhibit 38: Data Table on Comparison by Manufacturing Type
Exhibit 39: Chart on Captive APIs - Market size and forecast 2025-2030 ($ million)
Exhibit 40: Data Table on Captive APIs - Market size and forecast 2025-2030 ($ million)
Exhibit 41: Chart on Captive APIs - Year-over-year growth 2025-2030 (%)
Exhibit 42: Data Table on Captive APIs - Year-over-year growth 2025-2030 (%)
Exhibit 43: Chart on Contract APIs - Market size and forecast 2025-2030 ($ million)
Exhibit 44: Data Table on Contract APIs - Market size and forecast 2025-2030 ($ million)
Exhibit 45: Chart on Contract APIs - Year-over-year growth 2025-2030 (%)
Exhibit 46: Data Table on Contract APIs - Year-over-year growth 2025-2030 (%)
Exhibit 47: Market opportunity by Manufacturing Type ($ million)
Exhibit 48: Data Table on Market opportunity by Manufacturing Type ($ million)
Exhibit 49: Chart on Type - Market share 2025-2030 (%)
Exhibit 50: Data Table on Type - Market share 2025-2030 (%)
Exhibit 51: Chart on Comparison by Type
Exhibit 52: Data Table on Comparison by Type
Exhibit 53: Chart on Innovative APIs - Market size and forecast 2025-2030 ($ million)
Exhibit 54: Data Table on Innovative APIs - Market size and forecast 2025-2030 ($ million)
Exhibit 55: Chart on Innovative APIs - Year-over-year growth 2025-2030 (%)
Exhibit 56: Data Table on Innovative APIs - Year-over-year growth 2025-2030 (%)
Exhibit 57: Chart on Generic APIs - Market size and forecast 2025-2030 ($ million)
Exhibit 58: Data Table on Generic APIs - Market size and forecast 2025-2030 ($ million)
Exhibit 59: Chart on Generic APIs - Year-over-year growth 2025-2030 (%)
Exhibit 60: Data Table on Generic APIs - Year-over-year growth 2025-2030 (%)
Exhibit 61: Market opportunity by Type ($ million)
Exhibit 62: Data Table on Market opportunity by Type ($ million)
Exhibit 63: Chart on Product Type - Market share 2025-2030 (%)
Exhibit 64: Data Table on Product Type - Market share 2025-2030 (%)
Exhibit 65: Chart on Comparison by Product Type
Exhibit 66: Data Table on Comparison by Product Type
Exhibit 67: Chart on Prescription - Market size and forecast 2025-2030 ($ million)
Exhibit 68: Data Table on Prescription - Market size and forecast 2025-2030 ($ million)
Exhibit 69: Chart on Prescription - Year-over-year growth 2025-2030 (%)
Exhibit 70: Data Table on Prescription - Year-over-year growth 2025-2030 (%)
Exhibit 71: Chart on Over-the-counter (OTC) - Market size and forecast 2025-2030 ($ million)
Exhibit 72: Data Table on Over-the-counter (OTC) - Market size and forecast 2025-2030 ($ million)
Exhibit 73: Chart on Over-the-counter (OTC) - Year-over-year growth 2025-2030 (%)
Exhibit 74: Data Table on Over-the-counter (OTC) - Year-over-year growth 2025-2030 (%)
Exhibit 75: Market opportunity by Product Type ($ million)
Exhibit 76: Data Table on Market opportunity by Product Type ($ million)
Exhibit 77: Chart on Application - Market share 2025-2030 (%)
Exhibit 78: Data Table on Application - Market share 2025-2030 (%)
Exhibit 79: Chart on Comparison by Application
Exhibit 80: Data Table on Comparison by Application
Exhibit 81: Chart on Cardiovascular diseases (CVDs) - Market size and forecast 2025-2030 ($ million)
Exhibit 82: Data Table on Cardiovascular diseases (CVDs) - Market size and forecast 2025-2030 ($ million)
Exhibit 83: Chart on Cardiovascular diseases (CVDs) - Year-over-year growth 2025-2030 (%)
Exhibit 84: Data Table on Cardiovascular diseases (CVDs) - Year-over-year growth 2025-2030 (%)
Exhibit 85: Chart on Oncology - Market size and forecast 2025-2030 ($ million)
Exhibit 86: Data Table on Oncology - Market size and forecast 2025-2030 ($ million)
Exhibit 87: Chart on Oncology - Year-over-year growth 2025-2030 (%)
Exhibit 88: Data Table on Oncology - Year-over-year growth 2025-2030 (%)
Exhibit 89: Chart on Infectious diseases - Market size and forecast 2025-2030 ($ million)
Exhibit 90: Data Table on Infectious diseases - Market size and forecast 2025-2030 ($ million)
Exhibit 91: Chart on Infectious diseases - Year-over-year growth 2025-2030 (%)
Exhibit 92: Data Table on Infectious diseases - Year-over-year growth 2025-2030 (%)
Exhibit 93: Chart on Diabetes - Market size and forecast 2025-2030 ($ million)
Exhibit 94: Data Table on Diabetes - Market size and forecast 2025-2030 ($ million)
Exhibit 95: Chart on Diabetes - Year-over-year growth 2025-2030 (%)
Exhibit 96: Data Table on Diabetes - Year-over-year growth 2025-2030 (%)
Exhibit 97: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 98: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 99: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 100: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 101: Market opportunity by Application ($ million)
Exhibit 102: Data Table on Market opportunity by Application ($ million)
Exhibit 103: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 104: Impact of drivers and challenges in 2025 and 2030
Exhibit 105: Overview on criticality of inputs and factors of differentiation
Exhibit 106: Overview on factors of disruption
Exhibit 107: Impact of key risks on business
Exhibit 108: Companies covered
Exhibit 109: Company ranking index
Exhibit 110: Matrix on companies position and classification
Exhibit 111: Aurobindo Pharma Ltd. - Overview
Exhibit 112: Aurobindo Pharma Ltd. - Business segments
Exhibit 113: Aurobindo Pharma Ltd. - Key news
Exhibit 114: Aurobindo Pharma Ltd. - Key offerings
Exhibit 115: Aurobindo Pharma Ltd. - Segment focus
Exhibit 116: SWOT
Exhibit 117: Cipla Inc. - Overview
Exhibit 118: Cipla Inc. - Business segments
Exhibit 119: Cipla Inc. - Key news
Exhibit 120: Cipla Inc. - Key offerings
Exhibit 121: Cipla Inc. - Segment focus
Exhibit 122: SWOT
Exhibit 123: Divis Laboratories Ltd. - Overview
Exhibit 124: Divis Laboratories Ltd. - Product / Service
Exhibit 125: Divis Laboratories Ltd. - Key offerings
Exhibit 126: SWOT
Exhibit 127: Dr. Reddys Laboratories Ltd. - Overview
Exhibit 128: Dr. Reddys Laboratories Ltd. - Business segments
Exhibit 129: Dr. Reddys Laboratories Ltd. - Key news
Exhibit 130: Dr. Reddys Laboratories Ltd. - Key offerings
Exhibit 131: Dr. Reddys Laboratories Ltd. - Segment focus
Exhibit 132: SWOT
Exhibit 133: Glenmark Pharmaceuticals Ltd. - Overview
Exhibit 134: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibit 135: Glenmark Pharmaceuticals Ltd. - Key news
Exhibit 136: Glenmark Pharmaceuticals Ltd. - Key offerings
Exhibit 137: SWOT
Exhibit 138: Granules India Ltd. - Overview
Exhibit 139: Granules India Ltd. - Product / Service
Exhibit 140: Granules India Ltd. - Key offerings
Exhibit 141: SWOT
Exhibit 142: Ipca Laboratories - Overview
Exhibit 143: Ipca Laboratories - Product / Service
Exhibit 144: Ipca Laboratories - Key offerings
Exhibit 145: SWOT
Exhibit 146: Jubilant Pharmova Ltd. - Overview
Exhibit 147: Jubilant Pharmova Ltd. - Business segments
Exhibit 148: Jubilant Pharmova Ltd. - Key offerings
Exhibit 149: Jubilant Pharmova Ltd. - Segment focus
Exhibit 150: SWOT
Exhibit 151: Laurus Labs Ltd. - Overview
Exhibit 152: Laurus Labs Ltd. - Product / Service
Exhibit 153: Laurus Labs Ltd. - Key offerings
Exhibit 154: SWOT
Exhibit 155: Lupin Ltd. - Overview
Exhibit 156: Lupin Ltd. - Business segments
Exhibit 157: Lupin Ltd. - Key news
Exhibit 158: Lupin Ltd. - Key offerings
Exhibit 159: Lupin Ltd. - Segment focus
Exhibit 160: SWOT
Exhibit 161: Piramal Pharma Solutions - Overview
Exhibit 162: Piramal Pharma Solutions - Business segments
Exhibit 163: Piramal Pharma Solutions - Key offerings
Exhibit 164: Piramal Pharma Solutions - Segment focus
Exhibit 165: SWOT
Exhibit 166: Shilpa Medicare Ltd. - Overview
Exhibit 167: Shilpa Medicare Ltd. - Product / Service
Exhibit 168: Shilpa Medicare Ltd. - Key offerings
Exhibit 169: SWOT
Exhibit 170: Strides Pharma Ltd. - Overview
Exhibit 171: Strides Pharma Ltd. - Product / Service
Exhibit 172: Strides Pharma Ltd. - Key offerings
Exhibit 173: SWOT
Exhibit 174: Sun Pharmaceutical Industries - Overview
Exhibit 175: Sun Pharmaceutical Industries - Business segments
Exhibit 176: Sun Pharmaceutical Industries - Key news
Exhibit 177: Sun Pharmaceutical Industries - Key offerings
Exhibit 178: Sun Pharmaceutical Industries - Segment focus
Exhibit 179: SWOT
Exhibit 180: Syngene International Ltd. - Overview
Exhibit 181: Syngene International Ltd. - Product / Service
Exhibit 182: Syngene International Ltd. - Key offerings
Exhibit 183: SWOT
Exhibit 184: Inclusions checklist
Exhibit 185: Exclusions checklist
Exhibit 186: Currency conversion rates for US$
Exhibit 187: Research methodology
Exhibit 188: Information sources
Exhibit 189: Data validation
Exhibit 190: Validation techniques employed for market sizing
Exhibit 191: Data synthesis
Exhibit 192: 360 degree market analysis
Exhibit 193: List of abbreviations

Executive Summary

The following companies are recognized as the key players in the global active pharmaceutical ingredient (api) market in india: Aarti Industries Ltd., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Divis Laboratories Ltd., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Granules India Ltd., HIKAL Ltd., Ipca Laboratories, Jubilant Pharmova Ltd., Laurus Labs Ltd., Lupin Ltd., Neuland Laboratories, Piramal Pharma Solutions, Shilpa Medicare Ltd., Strides Pharma Ltd., Sun Pharmaceutical Industries, Syngene International Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is accelerated digitization and integration of artificial intelligence in process synthesis."

According to the report, one of the major drivers for this market is the rising domestic healthcare expenditure and prevalence of chronic conditions.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aarti Industries Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Aurobindo Pharma Ltd.
  • Cambrex Corp.
  • Cipla Inc.
  • Divis Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Granules India Ltd.
  • HIKAL Ltd.
  • Ipca Laboratories
  • Jubilant Pharmova Ltd.
  • Laurus Labs Ltd.
  • Lupin Ltd.
  • Neuland Laboratories
  • Piramal Pharma Solutions
  • Shilpa Medicare Ltd.
  • Strides Pharma Ltd.
  • Sun Pharmaceutical Industries
  • Syngene International Ltd.